Cover Image
市場調查報告書

亨丁頓舞蹈症:開發中產品分析

Huntington Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 362369
出版日期 內容資訊 英文 292 Pages
訂單完成後即時交付
價格
Back to Top
亨丁頓舞蹈症:開發中產品分析 Huntington Disease - Pipeline Review, H2 2016
出版日期: 2016年12月14日 內容資訊: 英文 292 Pages
簡介

本報告提供亨丁頓舞蹈症治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

亨丁頓舞蹈症概要

治療藥的開發

亨丁頓舞蹈症:企業開發中的治療藥

亨丁頓舞蹈症:大學/機關研究中的治療藥

亨丁頓舞蹈症:開發中產品概況

亨丁頓舞蹈症:企業開發中的產品

亨丁頓舞蹈症:大學/機關研究中的產品

亨丁頓舞蹈症的治療藥的開發企業

亨丁頓舞蹈症:治療藥的評估

藥物簡介

亨丁頓舞蹈症:最近的開發平台趨勢

亨丁頓舞蹈症:暫停中的計劃

亨丁頓舞蹈症:開發中止的產品

亨丁頓舞蹈症:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8805IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Pipeline Review, H2 2016, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10, 5, 46 and 17 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 19 and 4 molecules, respectively.Huntington Disease.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Huntington Disease Overview
  • Therapeutics Development
  • Huntington Disease - Therapeutics under Development by Companies
  • Huntington Disease - Therapeutics under Investigation by Universities/Institutes
  • Huntington Disease - Pipeline Products Glance
  • Huntington Disease - Products under Development by Companies
  • Huntington Disease - Products under Investigation by Universities/Institutes
  • Huntington Disease - Companies Involved in Therapeutics Development
  • Huntington Disease - Therapeutics Assessment
  • Drug Profiles
  • Huntington Disease - Dormant Projects
  • Huntington Disease - Discontinued Products
  • Huntington Disease - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Huntington Disease, H2 2016
  • Number of Products under Development for Huntington Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Huntington Disease - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Huntington Disease - Pipeline by AFFiRiS AG, H2 2016
  • Huntington Disease - Pipeline by Angita BV, H2 2016
  • Huntington Disease - Pipeline by Annexon Inc, H2 2016
  • Huntington Disease - Pipeline by Astellas Pharma Inc, H2 2016
  • Huntington Disease - Pipeline by Azevan Pharmaceuticals Inc, H2 2016
  • Huntington Disease - Pipeline by BioCrea GmbH, H2 2016
  • Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016
  • Huntington Disease - Pipeline by Celon Pharma Sp z oo, H2 2016
  • Huntington Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
  • Huntington Disease - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016
  • Huntington Disease - Pipeline by EncephRx Inc, H2 2016
  • Huntington Disease - Pipeline by Evotec AG, H2 2016
  • Huntington Disease - Pipeline by Galenea Corp, H2 2016
  • Huntington Disease - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016
  • Huntington Disease - Pipeline by Horizon Pharma Plc, H2 2016
  • Huntington Disease - Pipeline by Immungenetics AG, H2 2016
  • Huntington Disease - Pipeline by Ionis Pharmaceuticals Inc, H2 2016
  • Huntington Disease - Pipeline by Ipsen SA, H2 2016
  • Huntington Disease - Pipeline by Kadmon Corp LLC, H2 2016
  • Huntington Disease - Pipeline by KineMed Inc, H2 2016
  • Huntington Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H2 2016
  • Huntington Disease - Pipeline by Living Cell Technologies Ltd, H2 2016
  • Huntington Disease - Pipeline by Medesis Pharma SA, H2 2016
  • Huntington Disease - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016
  • Huntington Disease - Pipeline by Neuralstem Inc, H2 2016
  • Huntington Disease - Pipeline by Neurimmune Holding AG, H2 2016
  • Huntington Disease - Pipeline by NeuroNascent Inc, H2 2016
  • Huntington Disease - Pipeline by New World Laboratories Inc, H2 2016
  • Huntington Disease - Pipeline by nLife Therapeutics SL, H2 2016
  • Huntington Disease - Pipeline by NsGene A/S, H2 2016
  • Huntington Disease - Pipeline by Omeros Corp, H2 2016
  • Huntington Disease - Pipeline by Oryzon Genomics SA, H2 2016
  • Huntington Disease - Pipeline by Pfizer Inc, H2 2016
  • Huntington Disease - Pipeline by PharmatrophiX Inc, H2 2016
  • Huntington Disease - Pipeline by ProQR Therapeutics NV, H2 2016
  • Huntington Disease - Pipeline by QR Pharma Inc, H2 2016
  • Huntington Disease - Pipeline by reMYND NV, H2 2016
  • Huntington Disease - Pipeline by Retrotope Inc, H2 2016
  • Huntington Disease - Pipeline by Rhenovia Pharma Ltd, H2 2016
  • Huntington Disease - Pipeline by Shire Plc, H2 2016
  • Huntington Disease - Pipeline by SOM Biotech SL, H2 2016
  • Huntington Disease - Pipeline by Spark Therapeutics Inc, H2 2016
  • Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
  • Huntington Disease - Pipeline by TyrNovo Ltd, H2 2016
  • Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2016
  • Huntington Disease - Pipeline by UniQure NV, H2 2016
  • Huntington Disease - Pipeline by Vaccinex Inc, H2 2016
  • Huntington Disease - Pipeline by Vertex Pharmaceuticals Inc, H2 2016
  • Huntington Disease - Pipeline by VistaGen Therapeutics Inc, H2 2016
  • Huntington Disease - Pipeline by Vitality Biopharma Inc, H2 2016
  • Huntington Disease - Pipeline by VivaCell Biotechnology Espana SL, H2 2016
  • Huntington Disease - Pipeline by Voyager Therapeutics Inc, H2 2016
  • Huntington Disease - Pipeline by Vybion Inc, H2 2016
  • Huntington Disease - Pipeline by WAVE Life Sciences Ltd, H2 2016
  • Huntington Disease - Pipeline by Wellstat Therapeutics Corp, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Huntington Disease - Dormant Projects, H2 2016
  • Huntington Disease - Dormant Projects (Contd..1), H2 2016
  • Huntington Disease - Dormant Projects (Contd..2), H2 2016
  • Huntington Disease - Dormant Projects (Contd..3), H2 2016
  • Huntington Disease - Dormant Projects (Contd..4), H2 2016
  • Huntington Disease - Dormant Projects (Contd..5), H2 2016
  • Huntington Disease - Dormant Projects (Contd..6), H2 2016
  • Huntington Disease - Dormant Projects (Contd..7), H2 2016
  • Huntington Disease - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Huntington Disease, H2 2016
  • Number of Products under Development for Huntington Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top